Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer
Open accessAbstract
The Myc family of transcription factors are involved in the development and progression of numerous cancers, including prostate cancer (PCa). Under the pressure of androgen receptor (AR)-directed therapies resistance can occur, leading to the lethal form of PCa known as neuroendocrine prostate cancer (NEPC), characterized among other features by N-Myc overexpression. There are no clinically approved treatments for NEPC, translating into poor patient prognosis and survival. Therefore, there is a pressing need to develop novel therapeutic avenues to treat NEPC patients. In this study, we investigate the N-Myc-Max DNA binding domain (DBD) as a potential target for small molecule inhibitors and utilize computer-aided drug design (CADD) approaches to discover prospective hits. Through further exploration and optimization, a compound, VPC-70619, was identified with notable anti-N-Myc potency and strong antiproliferative activity against numerous N-Myc expressing cell lines, including those representing NEPC.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In 2022, Artem Cherkasov's research group discovered pockets of the Myc bHLHZ domain in a previous study, leading to the discovery of the compound VPC-70063 as a c-Myc inhibitor.
“In 2022, Artem Cherkasov’s research group discovered pockets of the Myc bHLHZ domain in a previous study, leading to the discovery of the compound VPC-70063 as a c-Myc inhibitor.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [473]
At 5 μM, VPC-70619 achieved nearly 100% transcriptional inhibition, and its proliferation inhibition and cell selectivity in n-Myc high expression cell lines were characterized.
“At 5 μM, it achieved nearly 100% transcriptional inhibition, and its proliferation inhibition and cell selectivity in n-Myc high expression cell lines were characterized.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [473]
VPC-70619 demonstrated strong inhibitory activity against n-Myc dependent cell lines and high bioavailability for oral and intraperitoneal administration.
“This compound demonstrated strong inhibitory activity against n-Myc dependent cell lines and high bioavailability for oral and intraperitoneal administration.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [473]
Through a series of molecular docking virtual screening and optimization, they subsequently obtained compound VPC-70619, a potent oral active n-Myc inhibitor that binds to the DNA binding region and prevents n-Myc/Max from binding to DNA.
“Through a series of molecular docking virtual screening and optimization, they subsequently obtained compound VPC-70619 (193) (Table 3), a potent oral active n-Myc inhibitor that binds to the DNA binding region and prevents n-Myc/Max from binding to DNA.473”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [473]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057 · see citing works
Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9644-8 · Cited by 6,130 · see citing works
ZINC 15 – Ligand Discovery for Everyone
Sterling, T., & Irwin, J. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00559 · Cited by 3,224 · cited 1× · see citing works
“Chemical Similarity Searches To identify potentially improved derivatives, high-similarity 3D structural searches were performed on the ZINC15 database [34] using the ROCS program from OpenEye [35].”
MethodOPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins.
Harder, E. D., Damm, W., Maple, J., Wu, C., Reboul, M., Xiang, J.-Y., Wang, L.-L., Lupyan, D., Dahlgren, M. K., Knight, J. L., et al. (2016) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5b00864 · Cited by 2,826 · cited 1× · see citing works
“3 Å, relative to the starting geometry [38].”
BackgroundNitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
Fleming, F. F., Yao, L., Ravikumar, P. C., Funk, L. A., & Shook, B. C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100762r · Cited by 1,764 · cited 1× · see citing works
“We observed that inclusion of nitriles is important for overall microsomal stability, in accordance with what has been proposed elsewhere [30].”
ResultHawkins, P. C. D., Skillman, A. G., Warren, G. L., Ellingson, B. A., & Stahl, M. T. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100031x · Cited by 1,635 · cited 1× · see citing works
“Omega2 from OpenEye (Santa Fe, NM, USA) was used to generate the different conformers of each searchable compound [36], and 2D substructure-based searches were performed against the ZINC15 database.”
MethodPrinciples and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology
Wilcken, R., Zimmermann, M. O., Lange, A., Joerger, A. C., & Boeckler, F. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3012068 · Cited by 1,364 · cited 1× · see citing works
“As previously highlighted, their inclusion as hydrophobic moieties could therefore be important as molecular interaction with weak to medium strength [29], specifically with Max’s sidechain in the proposed pocket.”
BackgroundThe MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad‐Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 1,010 · see citing works
Comparison of Shape-Matching and Docking as Virtual Screening Tools
Hawkins, P. C. D., Skillman, A. G., & Nicholls, A. O. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603365 · Cited by 998 · cited 3× · see citing works
“Omega2 from OpenEye (Santa Fe, NM, USA) was used to generate the different conformers of each searchable compound [36], and 2D substructure-based searches were performed against the ZINC15 database.”
MethodTargeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919 · see citing works
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 912 · cited 1× · see citing works
“Thus, we propose compound VPC-70619 as a single agent that could be effective with tolerable toxic effects within a specific therapeutic window, or as a chemotherapy agent which can be part of a combined oncogenic treatment regimen [31,32].”
BackgroundTargeting oncogenic Myc as a strategy for cancer treatment
Chen, H., Liu, H., & Qing, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0008-7 · Cited by 806 · cited 7× · see citing works
“Hence, development of novel molecules targeting N-Myc onco-driver has a great potential as therapeutic intervention for NEPC [7].”
BackgroundInfluentialThe future of cancer immunotherapy: microenvironment-targeting combinations
Murciano‐Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 753 · cited 1× · see citing works
“Thus, we propose compound VPC-70619 as a single agent that could be effective with tolerable toxic effects within a specific therapeutic window, or as a chemotherapy agent which can be part of a combined oncogenic treatment regimen [31,32].”
BackgroundSandhu, S. K., Moore, C. M., Chiong, E., Beltran, H., Bristow, R. G., & Williams, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00950-8 · Cited by 610 · see citing works
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
Dardenne, É., Beltran, H., Benelli, M., Gayvert, K. M., Berger, A., Puca, L., Cyrta, J., Sboner, A., Noorzad, Z., MacDonald, T. Y., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.005 · Cited by 561 · cited 2× · see citing works
“Given the high structural and functional similarity between the c-Myc and N-Myc oncoproteins [19,20], we used our previously-developed chemical series targeting MycMax/DBD complex as templates for the further development of novel N-Myc specific inhibitors [21,22].”
MethodSmall-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Han, H., Jain, A. D., Truica, M. I., Izquierdo-Ferrer, J., Anker, J. F., Lysy, B., Sagar, V., Luan, Y., Chalmers, Z. R., Unno, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.001 · Cited by 461 · cited 3× · see citing works
“and its improved analogue, MYCi975, were developed to directly bind to and inhibit Myc activity [17].”
BackgroundInfluentialN-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
Lee, J. K., Phillips, J. W., Smith, B. A., Park, J. W., Stoyanova, T. I., McCaffrey, E., Baertsch, R., Sokolov, A., Meyerowitz, J., Mathis, C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.001 · Cited by 410 · cited 8× · see citing works
“Hence, development of novel molecules targeting N-Myc onco-driver has a great potential as therapeutic intervention for NEPC [7].”
BackgroundInfluentialSelf-citationThe Role of Lineage Plasticity in Prostate Cancer Therapy Resistance
Beltran, H., Hruszkewycz, A. M., Scher, H. I., Hildesheim, J., Isaacs, J. S., Yu, E. Y., Kelly, K., Lin, D. W., Dicker, A. P., Arnold, J. T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1423 · Cited by 407 · see citing works
Self-citationClinical features of neuroendocrine prostate cancer
Conteduca, V., Oromendia, C., Eng, K., Bareja, R., Sigouros, M., Molina, A. M., Faltas, B. M., Sboner, A., Mosquera, J. M., Elemento, O., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.011 · Cited by 358 · see citing works
Oncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312 · cited 1× · see citing works
“Consequently, integrating novel CADD approaches would play an important role in targeting novel sites without classical properties, such as those with unusual and convex pocket shapes or transient protein–protein interactions [28].”
BackgroundBrockmann, M., Poon, E., Berry, T., Carstensen, A., Deubzer, H. E., Rycak, L., Jamin, Y., Thway, K., Robinson, S. P., Roels, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.005 · Cited by 300 · see citing works
Drugging MYCN through an Allosteric Transition in Aurora Kinase A
Gustafson, W. C., Meyerowitz, J., Nekritz, E. A., Chen, J., Benes, C. H., Charron, E., Simonds, E. F., Seeger, R. C., Matthay, K. K., Hertz, N. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.015 · Cited by 280 · see citing works
Alternative approaches to target Myc for cancer treatment
Wang, C., Zhang, J., Yin, J., Gan, Y., Xu, S., Gu, Y., & Huang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00500-y · Cited by 243 · see citing works
Roscovitine in cancer and other diseases.
Cicenas, J., Kalyan, K. P., Sorokinas, A., Stankunas, E., Levy, J., Meskinyte, I., Stankevičius, V., Kaupinis, A., & Valius, M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.03.61 · Cited by 222 · see citing works
Zhang, Y., Zheng, D., Zhou, T., Song, H., Hulsurkar, M. M., Su, N., Liu, Y., Wang, Z., Shao, L., Ittmann, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06177-2 · Cited by 213 · see citing works
Carabet, L. A., Rennie, P. S., & Cherkasov, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010120 · Cited by 172 · see citing works
Self-citationLoss of orally administered drugs in GI tract
Gavhane, Y. N., & Yadav, A. V. (2012) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2012.03.005 · Cited by 164 · cited 1× · see citing works
“Pharmacokinetic studies revealed that VPC-70619 has high bioavailability by the intraperitoneal and, importantly, oral administration, which both have distinct advantages as alternate routes over intravenous administration, most notably by avoiding the first-pass effect of hepatic metabolism [33].”
BackgroundDiscovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC
Boike, L., Cioffi, A. G., Majewski, F. C., Co, J., Henning, N. J., Jones, M. D., Liu, G., McKenna, J. M., Tallarico, J. A., Schirle, M., et al. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.09.001 · Cited by 154 · cited 1× · see citing works
“For example, compound EN4 was recently designed as a covalent ligand targeting the Cys171 residue within the intrinsically disordered region of Myc [16].”
BackgroundYin, Y., Xu, L., Chang, Y., Zeng, T., Chen, X., Wang, A., Groth, J., Foo, W., Liang, C. Y., Hu, H., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0941-2 · Cited by 113 · see citing works
A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer
Bai, S., Cao, S., Jin, L., Kobelski, M. M., Schouest, B., Wang, X., Ungerleider, N., Baddoo, M., Zhang, W., Corey, E., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0768-8 · Cited by 111 · cited 2× · see citing works
“Given the high structural and functional similarity between the c-Myc and N-Myc oncoproteins [19,20], we used our previously-developed chemical series targeting MycMax/DBD complex as templates for the further development of novel N-Myc specific inhibitors [21,22].”
MethodTherapy considerations in neuroendocrine prostate cancer: what next?
Beltran, H., & Demichelis, F. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0140 · Cited by 98 · see citing works
Redundancy: A Critical Obstacle to Improving Cancer Therapy
Lavi, O. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3256 · Cited by 68 · cited 1× · see citing works
“Targeting N-Myc directly could be advantageous to avoid the likelihood of resistance emerging due to redundancy and parallelism in the oncogenic pathways [26,27].”
BackgroundComputer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer
Carabet, L. A., Lallous, N., Leblanc, E., Ban, F., Morin, H., Lawn, S. O., Ghaidi, F., Lee, J., Mills, I. G., Gleave, M. E., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.023 · Cited by 54 · see citing works
Self-citationN-myc functions in transcription and development
Hurlin, P. J. (2005) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20059 · Cited by 51 · cited 1× · see citing works
“In addition, directly blocking Myc transcription might trigger unwanted side effects because of its central role in controlling gene expression in cells [12].”
BackgroundRadaeva, M., Ton, A., Hsing, M., Ban, F., & Cherkasov, A. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.018 · Cited by 44 · see citing works
Self-citationAntitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer
Seo, H. K., Ahn, K.-O., Jung, N.-R., Shin, J., Park, W. S., Lee, K. H., Lee, S.-J., & Jeong, K. (2014) · Oncotarget · doi:10.18632/oncotarget.1545 · Cited by 38 · cited 2× · see citing works
“Successful inhibition of the N-Myc-Max complex formation has shown to be an effective therapeutic strategy [25]; however, there are currently no clinically-approved compounds that were designed to interact directly with the N-MycMax DBD to treat PCa.”
BackgroundAre Parallel Proliferation Pathways Redundant?
Nussinov, R., Tsai, C., & Jang, H. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.03.013 · Cited by 33 · cited 1× · see citing works
“Targeting N-Myc directly could be advantageous to avoid the likelihood of resistance emerging due to redundancy and parallelism in the oncogenic pathways [26,27].”
BackgroundSingh, A. K., Kumar, A., Kumar, P., Nayak, N., Bhardwaj, T., Giri, R., & Garg, N. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100903 · Cited by 32 · cited 2× · see citing works
“Finally, L755507 is recent preclinical chemical d velop d to target heterodimerization of M c and Max to inhibi My transcription activation [18].”
BackgroundDual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer
Ton, A., Singh, K., Morin, H., Ban, F., Leblanc, E., Lee, J., Lallous, N., & Cherkasov, A. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218277 · Cited by 21 · cited 5× · see citing works
“For our bin ing pose predictions, the same homology mod l of N-Myc-Max DBD as described in our previous publication was used [22].”
MethodInfluentialSelf-citation
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Molecular mechanisms underlying the development of neuroendocrine prostate cancer
Liu, S., Alabi, B. R., Yin, Q., & Stoyanova, T. I. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.007 · Cited by 83 · see citing works
Recent advances from computer-aided drug design to artificial intelligence drug design
Wang, K., Huang, Y., Wang, Y., You, Q., & Wang, L. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00522h · Cited by 54 · see citing works
Yu, L., He, X. D., Fang, X., Liu, L., & Liu, J. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01371 · Cited by 25 · see citing works
Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer
Zamora, I., Freeman, M. R., Encı́o, I., & Rotinen, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813673 · Cited by 18 · see citing works
Cai, M., Zheng, F., Ren, Y.-Z., Zhen, C., Fu, D., Song, X., Li, Q., Qu, Y., Chen, Z., & Zhao, S. (2025) · Research · doi:10.34133/research.0791 · Cited by 12 · see citing works
Addressing the need for more therapeutic options in neuroendocrine prostate cancer
Kemble, J. P., Kwon, E. D., & Karnes, R. J. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2173174 · Cited by 11 · see citing works
Molteni, E., Baldan, F., Damante, G., & Allegri, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065993 · Cited by 10 · see citing works
“Considering the relevance of MYCN in the synergistic mechanism of action of GSK2801 and paclitaxel, we evaluated whether a specific small molecule inhibitor of MYCN (VPC70619) [31] would be able to alter the observed effects.”
BackgroundThe role of transcription factors in prostate cancer progression
Lee, J., & Lee, Y. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100193 · Cited by 6 · see citing works
Self-citationDrug targeting of protein-nucleic acid interactions
Genz, L. R., Nair, S. A., Sweeney, A., & Topf, M. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103165 · Cited by 5 · see citing works
García-Díaz, J. M., Garibaldi-Ríos, A. F., Gallegos‐Arreola, M. P., Gutiérrez-Gutiérrez, F., Delgado-Saucedo, J. I., Martínez‐Velázquez, M., & Puebla‐Pérez, A. M. (2026) · Scientia Pharmaceutica · doi:10.3390/scipharm94010009 · Cited by 2 · see citing works
Breaking the bonds: targeting protein dimerization for prostate cancer therapy
Singh, N., & Heemers, H. V. (2026) · Endocrinology · doi:10.1210/endocr/bqag056 · Cited by 1 · see citing works
The MYC network: Hub of malignancy and blueprint for intervention
Yin, H., Liu, T., & Pan, J. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189651 · Cited by 1 · see citing works
Ma, X., Tsalikis, A., Vernier, M., Zhu, K., Hassani, J. E., Ziegler, D. V., Huna, A., Coquet, C., Revêchon, G., Margand, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.28.610025 · Cited by 1 · see citing works
Aberrations of DNA Repair Pathways in Prostate Cancer—The State of the Art
Boussios, S., & Sheriff, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054301
Chemical intervention strategies targeting MYC for cancer therapy
Wu, D., Zhu, Y., Ye, M., Guo, X., Jiang, Z., & Zhang, X. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104726
BindingDB (2026) · UC San Diego · doi:10.7270/q2q52vj4
- Authors
- Ton, A.-T., Foo, J., Singh, K., Lee, J., Kalyta, A., Morin, H., Perez, C., Ban, F., Leblanc, E., Lallous, N., & Cherkasov, A.
- Affiliations
- University of British Columbia (CA)
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada
- Corresponding author
- Lallous, Nada
- Cherkasov, Artem
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-02-26
- Volume
- 23
- Issue
- 5
- Pages
- 2588
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8910697
- OpenAlex
- W4214688773
- Cited by
- 17
- References
- 40
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 1
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- cIRcle (University of British Columbia) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, cc-by)
- Open Collections
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- MYCN, neuroendocrine prostate cancer, small molecule inhibitors, computer-aided drug design, androgen receptor resistance, antiproliferative activity, drug discovery
- MeSH terms
- Humans, Male, Prospective Studies, Prostate, Prostatic Neoplasms, Receptors, Androgen, Gene Expression Regulation, Neoplastic, Carcinoma, Neuroendocrine, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
